Cost-Effectiveness of Transrectal and Transperineal Prostate Biopsy: Analysis From the ProBE-PC Randomized Study.
Fortis Gaba, Adrian J Waisman Malaret, Paul J Feustel et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized study-based cost analysis compared transrectal (TR-Bx) and transperineal prostate biopsy (TP-Bx), both performed under local anesthesia, in 718 men. Costs included supplies, personnel time, and complications, using actual institutional costs or payments. Procedural cost was higher with TP-Bx than TR-Bx ($323.78 vs $124.28; P < .001), largely reflecting disposable instrument costs and staff time. Complication counts were equal, and mean complication costs were similar. Total median cost, including complications, was also higher with TP-Bx ($326.78 vs $126.29, P < .005).
Key findings
- Procedural cost was higher for TP-Bx than TR-Bx ($323.78 vs $124.28; P < .001).
- Thirteen participants in each group experienced a complication; mean complication cost per biopsy was similar ($11.13 vs $19.26; P = .54).
- Total median cost of procedure plus complications was higher for TP-Bx ($326.78 vs $126.29, P < .005).
Why it matters
Biopsy technique choices have resource implications beyond the procedure itself. In this analysis, the higher cost of TP-Bx was driven mainly by disposable instruments and personnel time, while complication costs were similar between groups. These cost data can inform consideration of health care utilization alongside clinical outcomes when comparing biopsy approaches.
What to keep in mind
Costs were based on actual costs or payments at one institution, which may limit applicability to other settings.